advanced pancreatic cancer refractory to chemotherapy
Conditions
Interventions
irinotecan div day 1 and 15 in a 4-week course
Sponsors
The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with advanced or recurrent pancreatic cancer 2) Patients with pathologically confirmed pancreatic cancer 3) Patients refractory to gemcitabine and S-1 4) Patients with Eastern Chemotherapy Oncology Group(ECOG) performance status of 0-2 5) Patients of age >= 20 years 6) Patients have an adequate organ function 6) Patients have an ability for a sufficient oral intake 7) Written informed consent is required from all patients
Exclusion criteria
Exclusion criteria: 1) Patients with active infection 2) Patients with active GI bleeding 3) Patients with intestinal pneumonia, pulmonary fibrosis, and severe pulmonary emphysema 4) Patients with uncontrolled pleural effusion or ascites 5) Patients with watery diarrhea or ileus 6) Patients with synchronous or metachronous concomitant malignancies 7) Pregnant or lactating female or patients who are considering pregnancy 8) Patients with contraindication to irinotecan 9) Patients who are actively on other anticancer treatment 10) Inappropriate patients for entry on this study in the judgement of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate, disease control rate, progression free survival, 1-year survival rate, adverse events | — |
Countries
Japan
Contacts
Public ContactHiroyuki Isayama
The University of Tokyo Department of Gastroenterology, Graduate School of Medicine
Outcome results
None listed